3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Status
Unknown
1
Not yet recruiting
1
Completed
1
Sponsor Class
OTHER
254
INDUSTRY
48
NETWORK
9
UNKNOWN
6
OTHER_GOV
3
NIH
3
Study Type
Interventional
3
Sponsor
Cancer Type
Gastrointestinal
2
Breast
1
Conditions
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Neoplastic Cells, Circulating
1
Gastric Adenocarcinoma
1
Breast Neoplasms
1
Interventions
Capecitabine
28
apatinib
26
Oxaliplatin
24
Cisplatin
24
tislelizumab
23
Gemcitabine
23
Irinotecan
19
Paclitaxel
18
Carboplatin
18
Docetaxel
15
Bevacizumab
15
Fluorouracil
14
Drug Therapy
13
Cyclophosphamide
11
pembrolizumab
10
camrelizumab
10
Vinorelbine
9
Radiation
9
S 1 (combination)
8
Leucovorin
8
Cetuximab
8
toripalimab
7
sintilimab
7
Rituximab
7
Erlotinib Hydrochloride
7
pyrotinib
6
Gefitinib
6
Albumin-Bound Paclitaxel
6
fludarabine
5
anlotinib
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Phase 2
×
OTHER_GOV
×
130-nm albumin-bound paclitaxel
×
Clear all
NCT07610629
2026-05-28
RA-A-NP
Henan Cancer Hospital
Phase 2
Not yet recruiting
50 enrolled
NCT02707159
2023-03-08
PACT-ACT-v6
Helse Stavanger HF
Phase 2
Completed
70 enrolled
NCT01830244
2017-07-02
Neonab
Barwon Health
Phase 2
Unknown
60 enrolled